Don’t Stop Relieving: Journey’s DFD-29 Trounces Oracea In Reducing Rosacea Lesions
The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.
The company posted positive topline results from the Phase III MVOR-1 and MVOR-2 trials comparing DFD-29 against Galderma’s drug in papulopustular rosacea.